357 related articles for article (PubMed ID: 34552327)
1. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer.
Lu T; Prakash J
Int J Nanomedicine; 2021; 16():6313-6328. PubMed ID: 34552327
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
[TBL] [Abstract][Full Text] [Related]
3. A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer.
Tong QS; Miao WM; Huang H; Luo JQ; Liu R; Huang YC; Zhao DK; Shen S; Du JZ; Wang J
Small; 2021 Jul; 17(29):e2101208. PubMed ID: 34145747
[TBL] [Abstract][Full Text] [Related]
4. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
5. Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer.
Li YJ; Wu JY; Wang JM; Xiang DX
J Control Release; 2020 Apr; 320():105-111. PubMed ID: 31978441
[TBL] [Abstract][Full Text] [Related]
6. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer.
Ji T; Li S; Zhang Y; Lang J; Ding Y; Zhao X; Zhao R; Li Y; Shi J; Hao J; Zhao Y; Nie G
ACS Appl Mater Interfaces; 2016 Feb; 8(5):3438-45. PubMed ID: 26759926
[TBL] [Abstract][Full Text] [Related]
7. Cyclopamine treatment disrupts extracellular matrix and alleviates solid stress to improve nanomedicine delivery for pancreatic cancer.
Zhang B; Wang H; Jiang T; Jin K; Luo Z; Shi W; Mei H; Wang H; Hu Y; Pang Z; Jiang X
J Drug Target; 2018 Dec; 26(10):913-919. PubMed ID: 29533111
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicine in Pancreatic Cancer: A New Hope for Treatment.
Redruello P; Perazzoli G; Cepero A; Quiñonero F; Mesas C; Doello K; Láinez-Ramos-Bossini A; Rivera-Izquierdo M; Melguizo C; Prados J
Curr Drug Targets; 2020; 21(15):1580-1592. PubMed ID: 32619168
[TBL] [Abstract][Full Text] [Related]
9. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment.
Tanaka HY; Kano MR
Cancer Sci; 2018 Jul; 109(7):2085-2092. PubMed ID: 29737600
[TBL] [Abstract][Full Text] [Related]
10. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment.
Luo Y; Li C; Zhang Y; Liu P; Chen H; Zhao Z; Wang Y; Zhou Z; Song H; Su B; Li C; Li X; Zhang T; You H; Wu Y; Tian Z; Zhang S; Guo Y; Fan H; Chen Q; Jiang C; Sun T
Acta Biomater; 2023 Sep; 167():387-400. PubMed ID: 37276955
[TBL] [Abstract][Full Text] [Related]
11. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
Wang Z; Wu B; Nie G; Wei J; Li Y
Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836
[TBL] [Abstract][Full Text] [Related]
12. Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer.
Bian S; Dong H; Zhao L; Li Z; Chen J; Zhu X; Qiu N; Jia X; Song W; Li Z; Zheng S; Wang H; Song P
Adv Sci (Weinh); 2022 Oct; 9(29):e2201931. PubMed ID: 36026578
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue.
Longo V; Brunetti O; Gnoni A; Cascinu S; Gasparini G; Lorusso V; Ribatti D; Silvestris N
Oncotarget; 2016 Sep; 7(36):58649-58658. PubMed ID: 27462915
[TBL] [Abstract][Full Text] [Related]
14. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
Lafaro KJ; Melstrom LG
Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
[TBL] [Abstract][Full Text] [Related]
16. Barrier permeation and improved nanomedicine delivery in tumor microenvironments.
Liu J; Zhang J; Gao Y; Jiang Y; Guan Z; Xie Y; Hu J; Chen J
Cancer Lett; 2023 May; 562():216166. PubMed ID: 37028698
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
Song H; Jiang C
Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
[TBL] [Abstract][Full Text] [Related]
18. Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.
Li T; Wang YN; Khokhlova TD; D'Andrea S; Starr F; Chen H; McCune JS; Risler LJ; Mashadi-Hossein A; Hingorani SR; Chang A; Hwang JH
Cancer Res; 2015 Sep; 75(18):3738-46. PubMed ID: 26216548
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer.
Shah VM; Sheppard BC; Sears RC; Alani AW
Cancer Lett; 2020 Nov; 492():63-70. PubMed ID: 32822815
[TBL] [Abstract][Full Text] [Related]
20. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.
Meng H; Nel AE
Adv Drug Deliv Rev; 2018 May; 130():50-57. PubMed ID: 29958925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
